The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies
Open accessAbstract
Instability of vaccines often emerges as a key challenge during clinical development (lab to clinic) as well as commercial distribution (factory to patient). To yield stable, efficacious vaccine dosage forms for human use, successful formulation strategies must address a combination of interrelated topics including stabilization of antigens, selection of appropriate adjuvants, and development of stability-indicating analytical methods. This review covers key concepts in understanding the causes and mechanisms of vaccine instability including (1) the complex and delicate nature of antigen structures (e.g., viruses, proteins, carbohydrates, protein-carbohydrate conjugates, etc.), (2) use of adjuvants to further enhance immune responses, (3) development of physicochemical and biological assays to assess vaccine integrity and potency, and (4) stabilization strategies to protect vaccine antigens and adjuvants (and their interactions) during storage. Despite these challenges, vaccines can usually be sufficiently stabilized for use as medicines through a combination of formulation approaches combined with maintenance of an efficient cold chain (manufacturing, distribution, storage and administration). Several illustrative case studies are described regarding mechanisms of vaccine instability along with formulation approaches for stabilization within the vaccine cold chain. These include live, attenuated (measles, polio) and inactivated (influenza, polio) viral vaccines as well as recombinant protein (hepatitis B) vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Stabilization of vaccines and antibiotics in silk and eliminating the cold chain
Zhang, J., Pritchard, E., Hu, X., Valentin, T., Panilaitis, B., Omenetto, F. G., & Kaplan, D. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206210109 · Cited by 168
RetractedAkira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Arky, R. A. (1994) · Cited by 2,632
Pathogen Recognition by the Innate Immune System
Kumar, H., Kawai, T., & Akira, S. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2010.529976 · Cited by 2,257
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 2,077
Epidemiology and Prevention of Vaccine-Preventable Diseases
Atkinson, W. W. (2009) · Cited by 1,862
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
Immunology of hepatitis B virus and hepatitis C virus infection
Rehermann, B., & Nascimbeni, M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1573 · Cited by 1,627
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,451
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,303
Ten Great Public Health Achievements—United States, 1900-1999
(1999) · JAMA · doi:10.1001/jama.281.16.1481 · Cited by 1,298
Immunological mechanisms of vaccination
Pulendran, B., & Ahmed, R. (2011) · Nature Immunology · doi:10.1038/ni.2039 · Cited by 1,089
Picornaviridae : the viruses and their replication
Racaniello, V. R. (2001) · Medical Entomology and Zoology · Cited by 884
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Influenza A viruses: new research developments
Medina, R. A., & García-Sastre, A. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2613 · Cited by 677
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Self-citationKamerzell, T. J., Esfandiary, R., Joshi, S. B., Middaugh, C. R., & Volkin, D. B. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.07.006 · Cited by 510
Self-citationThe mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICS
GLEZEN, W. P. (1982) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036250 · Cited by 449
Complete nucleotide sequences of all three poliovirus serotype genomes
Toyoda, H., Kohara, M., Kataoka, Y., Suganuma, T., Omata, T., Imura, N., & Nomoto, A. (1984) · Journal of Molecular Biology · doi:10.1016/0022-2836(84)90084-6 · Cited by 418
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Influenza Vaccines for the Future
Lambert, L. C., & Fauci, A. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1002842 · Cited by 389
Flint, S. J. (2008) · Cited by 365
Aluminium adjuvants—in retrospect and prospect
Lindblad, E. B. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.032 · Cited by 362
Standing, O. (2002) · Cited by 351
Effect of vaccines on bacterial meningitis worldwide
McIntyre, P. B., O'Brien, K. L., Greenwood, B., & van de Beek, D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61187-8 · Cited by 326
Cellular Proteins in Influenza Virus Particles
Shaw, M. L., Stone, K. L., Colangelo, C. M., Gulcicek, E. E., & Palese, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000085 · Cited by 324 · cited 1×
“TEM micrograph of (A) live-attenuated influenza vaccine (LAIV) [200].”
BackgroundState of the world's vaccines and immunization
Brewer, J. M. (2003) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)90113-1 · Cited by 319
Freezing temperatures in the vaccine cold chain: A systematic literature review
Matthias, D. M., Robertson, J., Garrison, M. M., Newland, S., & Nelson, C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.052 · Cited by 304
Vaccine adjuvants: Current challenges and future approaches
Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21523 · Cited by 296
Hem, S. L., & HogenEsch, H. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.685 · Cited by 264
Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study
Wolfson, L. J., Strebel, P. M., Gacic-Dobo, M., Hoekstra, E. J., McFarland, J. W., & Hersh, B. S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60107-x · Cited by 259
The virosome concept for influenza vaccines
Huckriede, A., Bungener, L., Stegmann, T., Daemen, T., Medema, J., Palache, A. M., & Wilschut, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.026 · Cited by 250
Belnap, D. M., Filman, D. J., Trus, B. L., Cheng, N., Booy, F. P., Conway, J. F., Curry, S., Hiremath, C. N., Tsang, S. K., Steven, A. C., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1342-1354.2000 · Cited by 236
Opportunities and challenges of developing thermostable vaccines
Chen, D., & Kristensen, D. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.20 · Cited by 227
Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines
Zuckerman, J. N. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20524 · Cited by 223
Immunopathogenesis of hepatitis B virus infection
Chang, J. J., & Lewin, S. R. (2007) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100009 · Cited by 211
Cohen, B. J., Audet, S., Andrews, N., & Beeler, J. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.046 · Cited by 211
Josefsberg, J. O., & Buckland, B. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24493 · Cited by 201
Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J., & Middaugh, C. R. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10296 · Cited by 199
Self-citationNew hepatitis B vaccine formulated with an improved adjuvant system
Kundi, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.133 · Cited by 193
Tools and approaches to ensure quality of vaccines throughout the cold chain
Kartoğlu, Ü., & Milstien, J. B. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.923761 · Cited by 189
Antimicrobial preservative use in parenteral products: Past and present
Meyer, B. K., Ni, A., Hu, B., & Shi, L. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20976 · Cited by 187
Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities
Amorij, J.-P., Huckriede, A., Wilschut, J., Frijlink, H. W., & Hinrichs, W. L. J. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9559-6 · Cited by 186
Current and future issues in the manufacturing and development of monoclonal antibodies
Kozlowski, S., & Swann, P. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.002 · Cited by 170
Influenza virosomes as a vaccine adjuvant and carrier system
Moser, C., Amacker, M., & Zurbriggen, R. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.15 · Cited by 169
The ABC of clinical and experimental adjuvants—A brief overview
Brunner, R., Jensen‐Jarolim, E., & Pali‐Schöll, I. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.10.005 · Cited by 165
Alcock, R., Cottingham, M. G., Rollier, C. S., Furze, J., De Costa, S. D., Hanlon, M., Spencer, A. J., Honeycutt, J. D., Wyllie, D. H., Gilbert, S. C., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000490 · Cited by 161
Wang, K., Holtz, K. M., Anderson, K. E., Chubet, R. G., Mahmoud, W. M., & Cox, M. M. J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.005 · Cited by 145
Vaccines with Aluminum-containing Adjuvants: Optimizing Vaccine Efficacy and Thermal Stability
Clapp, T., Siebert, P., Chen, D., & Braun, L. J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22284 · Cited by 143
Heat-stable measles vaccine produced by spray drying
Ohtake, S., Martin, R. A., Yee, L., Chen, D., Kristensen, D. D., Lechuga‐Ballesteros, D., & Truong-Le, V. L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.024 · Cited by 140
Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
Garçon, N., Morel, S., Didierlaurent, A. M., Descamps, D., Wettendorff, M. A., & Mechelen, M. V. (2011) · BioDrugs · doi:10.2165/11591760-000000000-00000 · Cited by 137
Evans, R. K., Xu, Z. Z., Bohannon, K. E., Wang, B., Bruner, M. W., & Volkin, D. B. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200001)89:1<76::aid-jps8>3.0.co;2-u · Cited by 130
Self-citationHansen, B., Sokolovska, A., HogenEsch, H., & Hem, S. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.049 · Cited by 126
Devices for intradermal vaccination
Kis, E. E., Winter, G., & Myschik, J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.020 · Cited by 126
Multidimensional methods for the formulation of biopharmaceuticals and vaccines
Maddux, N. R., Joshi, S. B., Volkin, D. B., Ralston, J. P., & Middaugh, C. R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22618 · Cited by 112
Self-citationHepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.
(2004) · Europe PMC (PubMed Central) · Cited by 97
Djingarey, M. H., Barry, R., Bonkoungou, M., Tiendrebeogo, S. R. M., Sebgo, R., Kandolo, D., Lingani, C., Préziosi, M., ZUBER, P. L. F., Perea, W., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.073 · Cited by 96
Bröker, M., Dull, P. M., Rappuoli, R., & Costantino, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.036 · Cited by 87
Krenn, B. M., Egorov, A., Romanovskaya-Romanko, E., Wolschek, M. F., Nakowitsch, S., Ruthsatz, T., Kiefmann, B., Morokutti, A., Humer, J., Geiler, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018577 · Cited by 84
TLR4 agonists as immunomodulatory agents
Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P. (2006) · Journal of Endotoxin Research · doi:10.1179/096805106x118753 · Cited by 80
Vaccine stabilization: Research, commercialization, and potential impact
Kristensen, D. D., Chen, D., & Cummings, R. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.070 · Cited by 79
Evaluation of the Cold-Chain for Oral Polio Vaccine in a Rural District of India
Samant, Y., Lanjewar, H., Parker, D., Block, L. E., Tomar, G. S., & Stein, B. (2007) · Public Health Reports · doi:10.1177/003335490712200116 · Cited by 79
Measles: Old Vaccines, New Vaccines
Griffin, D. E., & Pan, C. H. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70617-5_10 · Cited by 71
Characterization of the freeze sensitivity of a hepatitis B vaccine
Chen, D., Tyagi, A., Carpenter, J. P., Perkins, S., Sylvester, D., Guy, M., Kristensen, D. D., & Braun, L. J. (2009) · Human Vaccines · doi:10.4161/hv.5.1.6494 · Cited by 71
Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants
Braun, L. J., Tyagi, A., Perkins, S., Carpenter, J. P., Sylvester, D., Guy, M., Kristensen, D. D., & Chen, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.027 · Cited by 70
Effects of Stabilizers on the Destabilization of Proteins upon Adsorption to Aluminum Salt Adjuvants
Peek, L. J., Martin, T. T., Nation, C. E., Pegram, S. A., & Middaugh, C. R. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20762 · Cited by 70
Self-citationLyophilization and the Thermostability of Vaccines
Rexroad, J., Wiethoff, C. M., Jones, L. S., & Middaugh, C. R. (2002) · Cell Preservation Technology · doi:10.1089/153834402320882593 · Cited by 70
Self-citationCharacterization of a thermostable hepatitis B vaccine formulation
Braun, L. J., Jezek, J., Peterson, S., Tyagi, A., Perkins, S., Sylvester, D., Guy, M., Lal, M., Priddy, S., Plzak, H., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.069 · Cited by 67
Stabilization of measles virus for vaccine formulation
Kissmann, J. M., Ausar, S. F., Rudolph, A. R., Braun, C. S., Cape, S. P., Sievers, R. E., Federspiel, M. J., Joshi, S. B., & Middaugh, C. R. (2008) · Human Vaccines · doi:10.4161/hv.4.5.5863 · Cited by 67
Self-citationShi, Y., HogenEsch, H., & Hem, S. L. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00313-9 · Cited by 65
Validation of the shake test for detecting freeze damage to adsorbed vaccines
Kartoğlu, Ü., Özgüler, N. K., Wolfson, L. J., & KURZĄTKOWSKI, W. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.08.056879 · Cited by 62
Schlehuber, L. D., McFadyen, I. J., Shu, Y., Carignan, J., Duprex, W. P., Forsyth, W. R., Ho, J. H., Kitsos, C. M., Lee, G. Y., Levinson, D. A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.04.079 · Cited by 60
Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens
Dey, A., & Srivastava, I. K. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.142 · Cited by 60
Forced degradation studies: an essential tool for the formulation development of vaccines
Ausar, S. F., Hasija, Li, L., & Rahman (2013) · Vaccine Development and Therapy · doi:10.2147/vdt.s41998 · Cited by 58
Six Revolutions in Vaccinology
Plotkin, S. A. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000148933.08301.02 · Cited by 58
Maturation of Recombinant Hepatitis B Virus Surface Antigen Particles
Zhao, Q., Wanga, Y., Freedb, D., Fub, T.-M., Gimeneza, J. A., Sitrina, R. D., & Washabaugh, M. W. (2006) · Human Vaccines · doi:10.4161/hv.2.4.3015 · Cited by 55
Quality-control issues and approaches in vaccine development
Metz, B., van den Dobbelsteen, G., van Els, C. A. C. M., van der Gun, J., Levels, L., van der Pol, L., Rots, N. Y., & Kersten, G. F. A. (2009) · Expert Review of Vaccines · doi:10.1586/14760584.8.2.227 · Cited by 54
Heat stability of a recombinant DNA hepatitis B vaccine
Damme, P. V., Cramm, M., Safary, A., Vandepapelière, P., & Meheus, A. (1992) · Vaccine · doi:10.1016/0264-410x(92)90064-q · Cited by 51
Feshchenko, E. A., Rhodes, D. G., Felberbaum, R., McPherson, C. E., Rininger, J. A., Post, P. L., & Cox, M. M. J. (2012) · BMC Biotechnology · doi:10.1186/1472-6750-12-77 · Cited by 49
Edstam, J. S., Dulmaa, N., Nymadawa, P., Rinchin, A., Khulan, J., & Kimball, A. M. (2002) · Preventive Medicine · doi:10.1006/pmed.2001.0972 · Cited by 47
Assessing the effectiveness of cold chain management for childhood vaccines
Turner, N. M., Laws, A., & Roberts, L. (2011) · Journal of Primary Health Care · doi:10.1071/hc11278 · Cited by 45
Structural damages in adsorbed vaccines affected by freezing
KURZĄTKOWSKI, W., Kartoğlu, Ü., Staniszewska, M., Górska, P., Krause, A., & Wysocki, M. J. (2011) · Biologicals · doi:10.1016/j.biologicals.2011.10.011 · Cited by 44
Live viral vaccine potency: an index for assessing the cold chain system
Acu, F., Adedeji, A. O., Esan, J., & Odusanya, O. (1996) · Public Health · doi:10.1016/s0033-3506(96)80003-5 · Cited by 42
Ausar, S. F., Chan, J., Hoque, W., James, O., Jayasundara, K., & Harper, K. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22282 · Cited by 41
Thermostabilization of live virus vaccines by heavy water (D2O)
Wu, R., Georgescu, M. M., Delpeyroux, F., Guillot, S., Balanant, J., Simpson, K., & Crainic, R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00068-c · Cited by 41
Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material
Luykx, D. M. A. M., Casteleijn, M. G., Jiskoot, W., Westdijk, J., & Jongen, P. M. J. M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.05.007 · Cited by 39
Edstam, J. S., Dulmaa, N., Tsendjav, O., Dambasuren, B., & Densmaa, B. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.01.029 · Cited by 38
Principi, N., & Esposito, S. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18011 · Cited by 38
Development of a More Thermostable Poliovirus Vaccine
Milstien, J. B., Lemon, S. M., & Wright, P. F. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s247 · Cited by 37
A Rational, Systematic Approach for the Development of Vaccine Formulations
Morefield, G. L. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9261-1 · Cited by 37
Evaluation of an outside-the-Cold-Chain Vaccine Delivery Strategy in Remote Regions of Western China
Ren, Q., Xiong, H., Li, Y., Xu, R., & Zhu, C. (2009) · Public Health Reports · doi:10.1177/003335490912400517 · Cited by 35
Lessons Learned From a Review of the Development of Selected Vaccines
Committee, N. V. A. (1999) · PEDIATRICS · doi:10.1542/peds.104.4.942 · Cited by 34
Dambadarjaa, D., Ojima, T., Wiersma, S., Lkhagvasuren, T., Nymadawa, P., Uehara, R., Watanabe, M., Oki, I., & Nakamura, Y. (2007) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2006.051375 · Cited by 32
H1N1 Influenza Virus-Like Particles: Physical Degradation Pathways and Identification of Stabilizers
Kissmann, J. M., Joshi, S. B., Haynes, J. R., Dokken, L., Richardson, C., & Middaugh, C. R. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22304 · Cited by 30
Self-citationThermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation
Rombaut, B., Verheyden, B., Andries, K., & Boeyé, A. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6454-6457.1994 · Cited by 29
Desirable Attributes of Vaccines for Deployment in Low-Resource Settings
Chen, D., & Zehrung, D. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23352 · Cited by 29
Progress Towards a Needle-Free Hepatitis B Vaccine
Lebre, F., Borchard, G., de Lima, M. C. P., & Borges, O. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0314-4 · Cited by 29
Belshe, R. B., WALKER, R. E., Stoddard, J. J., Kemble, G. W., Maassab, H. F., & Mendelman, P. M. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50020-9 · Cited by 27
Developments in the production and quality control of poliovirus vaccines – Historical perspectives
Furesz, J. (2006) · Biologicals · doi:10.1016/j.biologicals.2006.02.008 · Cited by 25
A review of multiple approaches towards an improved hepatitis B vaccine
Sanyal, G., & Shi, L. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770802587226 · Cited by 23
Analysis of Cationic-Lipid?Plasmid-DNA Complexes
Ramsey, C. R. M. A. J. D. (2007) · Analytical Chemistry · doi:10.1021/ac0719711 · Cited by 22
Iyer, V., Liyanage, M. R., Shôji, Y., Chichester, J. A., Jones, R. M., Yusibov, V. M., Joshi, S. B., & Middaugh, C. R. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19106 · Cited by 19
Self-citationWang, T., Joshi, S. B., Kumru, O. S., Telikepalli, S. N., Middaugh, C. R., & Volkin, D. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4316-2_9 · Cited by 15
Self-citationUse of cool water packs to prevent freezing during vaccine transportation at the country level.
Kartoğlu, Ü., Ganivet, S., Guichard, S., Aiyer, V., Bollen, P., Maire, D., & Altay, B. (2009) · PubMed · Cited by 13
Lyophilization and Stabilization of Vaccines
Chesko, J., Fox, C., Dutill, T. S., Vedvick, T., & Reed, S. (2011) · Wiley eBooks · doi:10.1002/9781118023648.ch14 · Cited by 12
The Role of Adjuvant in Mediating Antigen Structure and Stability
Braun, L. J., Eldridge, A. M., Cummiskey, J., Arthur, K. K., & Wuttke, D. S. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23039 · Cited by 10
Efforts to improve vaccine stabilization heat up
Wadman, M. (2009) · Nature Medicine · doi:10.1038/nm1109-1232 · Cited by 3
Cited by
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
“Although subunit vaccines based on recombinant protein antigens have several intrinsic advantages over other vaccine modalities, they must meet stringent requirements related to stability during manufacture, storage, and distribution (Kumru et al., 2014).”
Portable, On-Demand Biomolecular Manufacturing
Pardee, K., Slomovic, S., Nguyen, P. Q., Lee, J. W., Donghia, N., Burrill, D., Ferrante, T., McSorley, F. R., Furuta, Y., Vernet, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.013 · Cited by 333
Pettinari, C., Pettinari, R., Di Nicola, C., Tombesi, A., Scuri, S., & Marchetti, F. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214121 · Cited by 329
Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
Novel approaches for the design, delivery and administration of vaccine technologies
Wallis, J., Shenton, D. P., & Carlisle, R. C. (2019) · Clinical and Experimental Immunology · doi:10.1111/cei.13287 · Cited by 123
Metadata
- Authors
- Kumru, O. S., Joshi, S. B., Smith, D. E., Middaugh, C. R., Prusik, T., & Volkin, D. B.
- Venue
- Biologicals
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 42
- Issue
- 5
- Pages
- 237-259
- ISSN
- 1045-1056 (ISSN-L)
- OpenAlex
- W1963498445
- Cited by
- 404
- References
- 111
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.